long intergenic non-protein coding RNA 2818Genealiases: []
Q-omics provides the consensus-scored LINC02818 profile across patient tissues and cancer cell-line models. LINC02818 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, LINC02818 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, LINC02818 RNA expression shows 14,551 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight CESC, HNSC, and ACC as cancer lineages where LINC02818 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02818 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02818 survival associations across molecular data types. LINC02818 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02818 RNA expression–survival associations across cancer types. High LINC02818 expression shows unfavorable associations in CESC, ACC, MESO and LGG, but favorable associations in SKCM and UCS. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for LINC02818 RNA expression.
This table summarizes LINC02818 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02818. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02818 shows higher tumor expression in HNSC, LIHC, BLCA, LUSC, BRCA and STAD. The HNSC box plot shows higher LINC02818 RNA expression in tumor versus normal tissue (log2 FC = +0.413, t-test p < 0.001).
This table shows molecular features associated with LINC02818 in patient tissues and cancer cell lines. In patient samples, LINC02818 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
